Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.

Martinez-Ramirez D, Okun MS, Jaffee MS.

Neurodegener Dis Manag. 2016 Jul 13. [Epub ahead of print]

PMID:
27408981
2.

Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Chang A, Fox SH.

Drugs. 2016 Jul;76(11):1093-118. doi: 10.1007/s40265-016-0600-5. Review.

PMID:
27312429
3.

Pimavanserin: First Global Approval.

Markham A.

Drugs. 2016 Jul;76(10):1053-7. doi: 10.1007/s40265-016-0597-9.

PMID:
27262680
4.

Pimavanserin approved for Parkinson's-related hallucinations, delusions.

Traynor K.

Am J Health Syst Pharm. 2016 Jun 15;73(12):853. doi: 10.2146/news160037. No abstract available.

PMID:
27261226
5.

Pimavanserin (Nuplazid) for Parkinson's disease psychosis.

[No authors listed]

Med Lett Drugs Ther. 2016 Jun 6;58(1496):74-5. No abstract available.

PMID:
27249096
6.

Pimavanserin: An Inverse Agonist Antipsychotic Drug.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2016 Jun 1;54(6):21-4. doi: 10.3928/02793695-20160523-01.

PMID:
27245248
7.

Psychosis in Parkinson's disease: unexplained observations in a seemingly simple model.

Friedman JH, Akbar U.

Expert Rev Neurother. 2016 Jun;16(6):595-6. doi: 10.1586/14737175.2016.1162713. Epub 2016 Mar 30. No abstract available.

PMID:
26949843
8.

The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.

Hermanowicz S, Hermanowicz N.

Expert Rev Neurother. 2016 Jun;16(6):625-33. doi: 10.1586/14737175.2016.1158102.

PMID:
26908168
9.

Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators.

Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata N.

J Alzheimers Dis. 2015;50(3):733-40. doi: 10.3233/JAD-150818.

PMID:
26757194
10.

Pimavanserin.

Hunter NS, Anderson KC, Cox A.

Drugs Today (Barc). 2015 Nov;51(11):645-52. doi: 10.1358/dot.2015.51.11.2404001. Review.

PMID:
26744739
11.

New clinical trials for nonmotor manifestations of Parkinson's disease.

Schrag A, Sauerbier A, Chaudhuri KR.

Mov Disord. 2015 Sep 15;30(11):1490-504. doi: 10.1002/mds.26415. Review.

PMID:
26371623
12.

Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.

Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn DJ.

J Am Med Dir Assoc. 2015 Oct 1;16(10):898.e1-7. doi: 10.1016/j.jamda.2015.06.021. Epub 2015 Aug 1.

13.

Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.

Cummings J, Zhong K.

Clin Pharmacol Ther. 2015 Nov;98(5):483-5. doi: 10.1002/cpt.190. Epub 2015 Aug 31. Review.

PMID:
26206713
15.

Comprehensive treatment of dementia with Lewy bodies.

Boot BP.

Alzheimers Res Ther. 2015 May 29;7(1):45. doi: 10.1186/s13195-015-0128-z. eCollection 2015.

16.

(11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand.

Andersen VL, Hansen HD, Herth MM, Dyssegaard A, Knudsen GM, Kristensen JL.

Bioorg Med Chem Lett. 2015 Mar 1;25(5):1053-6. doi: 10.1016/j.bmcl.2015.01.017. Epub 2015 Jan 20.

PMID:
25655720
17.

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

Broadstock M, Ballard C, Corbett A.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):779-86. doi: 10.1586/17512433.2014.966814. Epub 2014 Oct 10. Review.

PMID:
25301532
18.

Treating psychosis in movement disorder patients: a review.

Borek LL, Friedman JH.

Expert Opin Pharmacother. 2014 Aug;15(11):1553-64. doi: 10.1517/14656566.2014.918955. Epub 2014 May 20. Review.

PMID:
24846479
19.

On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.

Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H.

Neurochem Res. 2014 Oct;39(10):2008-17. doi: 10.1007/s11064-014-1293-3. Epub 2014 Mar 30. Review.

20.

Treatment of psychosis and dementia in Parkinson's disease.

Goldman JG, Holden S.

Curr Treat Options Neurol. 2014 Mar;16(3):281. doi: 10.1007/s11940-013-0281-2.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk